Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2
Despite initial findings indicating that SARS-CoV and SARS-CoV-2 are genetically related belonging to the same virus species and that the two viruses used the same entry receptor, angiotensin-converting enzyme 2 (ACE2), our data demonstrated that there is no detectable cross-neutralization by SARS p...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2020.1761267 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850200446443978752 |
|---|---|
| author | Danielle E. Anderson Chee Wah Tan Wan Ni Chia Barnaby E. Young Martin Linster JennyG. H. Low Yee-Joo Tan Mark I.-C. Chen Gavin J. D. Smith Yee Sin Leo David C. Lye Lin-Fa Wang |
| author_facet | Danielle E. Anderson Chee Wah Tan Wan Ni Chia Barnaby E. Young Martin Linster JennyG. H. Low Yee-Joo Tan Mark I.-C. Chen Gavin J. D. Smith Yee Sin Leo David C. Lye Lin-Fa Wang |
| author_sort | Danielle E. Anderson |
| collection | DOAJ |
| description | Despite initial findings indicating that SARS-CoV and SARS-CoV-2 are genetically related belonging to the same virus species and that the two viruses used the same entry receptor, angiotensin-converting enzyme 2 (ACE2), our data demonstrated that there is no detectable cross-neutralization by SARS patient sera against SARS-CoV-2. We also found that there are significant levels of neutralizing antibodies in recovered SARS patients 9–17 years after initial infection. These findings will be of significant use in guiding the development of serologic tests, formulating convalescent plasma therapy strategies, and assessing the longevity of protective immunity for SARS-related coronaviruses in general as well as vaccine efficacy. |
| format | Article |
| id | doaj-art-00cfe039fd8646cf8bc24dc32ec53072 |
| institution | OA Journals |
| issn | 2222-1751 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-00cfe039fd8646cf8bc24dc32ec530722025-08-20T02:12:20ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512020-01-019190090210.1080/22221751.2020.1761267Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2Danielle E. Anderson0Chee Wah Tan1Wan Ni Chia2Barnaby E. Young3Martin Linster4JennyG. H. Low5Yee-Joo Tan6Mark I.-C. Chen7Gavin J. D. Smith8Yee Sin Leo9David C. Lye10Lin-Fa Wang11Duke-NUS Medical School, Singapore, SingaporeDuke-NUS Medical School, Singapore, SingaporeDuke-NUS Medical School, Singapore, SingaporeNational Center for Infectious Diseases, Singapore, SingaporeDuke-NUS Medical School, Singapore, SingaporeSingapore General Hospital, Singapore, SingaporeNational University of Singapore, Singapore, SingaporeNational Center for Infectious Diseases, Singapore, SingaporeDuke-NUS Medical School, Singapore, SingaporeNational Center for Infectious Diseases, Singapore, SingaporeNational Center for Infectious Diseases, Singapore, SingaporeDuke-NUS Medical School, Singapore, SingaporeDespite initial findings indicating that SARS-CoV and SARS-CoV-2 are genetically related belonging to the same virus species and that the two viruses used the same entry receptor, angiotensin-converting enzyme 2 (ACE2), our data demonstrated that there is no detectable cross-neutralization by SARS patient sera against SARS-CoV-2. We also found that there are significant levels of neutralizing antibodies in recovered SARS patients 9–17 years after initial infection. These findings will be of significant use in guiding the development of serologic tests, formulating convalescent plasma therapy strategies, and assessing the longevity of protective immunity for SARS-related coronaviruses in general as well as vaccine efficacy.https://www.tandfonline.com/doi/10.1080/22221751.2020.1761267SARSCOVID-19antibodycross-neutralizationSARS-CoV-2 |
| spellingShingle | Danielle E. Anderson Chee Wah Tan Wan Ni Chia Barnaby E. Young Martin Linster JennyG. H. Low Yee-Joo Tan Mark I.-C. Chen Gavin J. D. Smith Yee Sin Leo David C. Lye Lin-Fa Wang Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2 Emerging Microbes and Infections SARS COVID-19 antibody cross-neutralization SARS-CoV-2 |
| title | Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2 |
| title_full | Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2 |
| title_fullStr | Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2 |
| title_full_unstemmed | Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2 |
| title_short | Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2 |
| title_sort | lack of cross neutralization by sars patient sera towards sars cov 2 |
| topic | SARS COVID-19 antibody cross-neutralization SARS-CoV-2 |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2020.1761267 |
| work_keys_str_mv | AT danielleeanderson lackofcrossneutralizationbysarspatientseratowardssarscov2 AT cheewahtan lackofcrossneutralizationbysarspatientseratowardssarscov2 AT wannichia lackofcrossneutralizationbysarspatientseratowardssarscov2 AT barnabyeyoung lackofcrossneutralizationbysarspatientseratowardssarscov2 AT martinlinster lackofcrossneutralizationbysarspatientseratowardssarscov2 AT jennyghlow lackofcrossneutralizationbysarspatientseratowardssarscov2 AT yeejootan lackofcrossneutralizationbysarspatientseratowardssarscov2 AT markicchen lackofcrossneutralizationbysarspatientseratowardssarscov2 AT gavinjdsmith lackofcrossneutralizationbysarspatientseratowardssarscov2 AT yeesinleo lackofcrossneutralizationbysarspatientseratowardssarscov2 AT davidclye lackofcrossneutralizationbysarspatientseratowardssarscov2 AT linfawang lackofcrossneutralizationbysarspatientseratowardssarscov2 |